



Biotech Daily

Thursday November 28, 2019

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH UP: RESONANCE UP 13%; PRESCIENT DOWN 12%**
- * **ELLEX 80% REVENUE LASER, ULTRASOUND SALE SUSPENSION**
- * **FEDERAL \$20m FOR OVARIAN CANCER RESEARCH**
- * **PRO MEDICUS LAUNCHES VISAGE AI ACCELERATOR**
- * **RESONANCE, SIEMENS PARTNER FOR FERRISMART**
- * **CRESO TO RAISE UP TO \$10m FOR PHARMACIELO, OPERATIONS**
- * **DORSAVI NOTES, PLACEMENT RAISE \$1.7m; PLAN FOR \$1m MORE**
- * **FDA OKAYS IMPEDIMED SOZO FOR PROTEIN CALORIE MALNUTRITION**
- * **RESAPP TO COMBINE DIAGNOSTIC WITH COVIU PLATFORM**
- * **RESAPP 40% OPPOSE DIRECTOR OPTIONS**
- * **OPTISCAN 19% OPPOSE 10 PERCENT PLACEMENT FACILITY**
- * **PAINCHEK DIRECTORS SELL 45m SHARES TO FUND TAX LIABILITY**
- * **IMUGENE REQUESTS CAPITAL RAISING TRADING HALT**
- * **SIENNA TAKES CAPITAL RAISING TRADING HALT TO SUSPENSION**
- * **NOXOPHARM REQUESTS NOX66 CANCER TRIAL RESULTS HALT**

MARKET REPORT

The Australian stock market was up 0.2 percent on Thursday November 28, 2019, with the ASX200 up 13.4 points to 6,864.0 points. Nineteen of the Biotech Daily Top 40 stocks were up, 12 fell, five traded unchanged and four were untraded.

Resonance was the best, up 2.5 cents or 13.2 percent to 21.5 cents with 10.8 million shares traded. Optiscan climbed 10 percent; Paradigm was up 7.1 percent; Orthocell improved 6.2 percent; Genetic Signatures and Universal Biosensors were up more than five percent; Antisense, Kazia, Opthea, Polynovo and Proteomics were up more than three percent; Clinuvel, Impedimed and LBT rose more than two percent; Avita, Cochlear, CSL, Starpharma and Volpara were up more than one percent; with Cynata and Medical Developments up by less than one percent.

Yesterday's 33.3 percent best, Prescient, led the falls, down 1.2 cents or 12.0 percent to 8.8 cents with 49.7 million shares traded. Actinogen lost 6.5 percent; Next Science fell 3.5 percent; Impedimed, Oncosil, Patrys and Pro Medicus shed two percent or more; Compumedics, Mesoblast and Neuren were down more than one percent; with Nanosonics and Telix down by less than one percent.

ELLEX MEDICAL LASERS

Ellex says it has requested a suspension until December 12, 2019 to finalize "the proposed sale of [its] lasers and ultrasound business segment".

In its annual report, the company said it had three business segments: 1. laser and ultrasound; 2. Ellex Itrack; and 3. 2RT.

The annual report said that of the total \$81,637,000 in revenue for the year to June 30, 2019, the laser and ultrasound business was responsible for \$65,522,000 (80.3%), with Itrack contributing \$14,324,000 and 2RT \$1,791,000.

Ellex last traded at 61 cents.

FEDERAL GOVERNMENT

The Federal Government says it will provide \$20 million for research grants for ovarian cancer, opening today.

A media release from Federal Health Minister Greg Hunt said that ovarian cancer was estimated to be the tenth most commonly diagnosed cancer in Australian women and there was "no reliable early detection screening test".

"We are supporting research that leads to improved diagnosis and treatment of ovarian cancer," Mr Hunt said.

The media release said the funds for the grants would come from the Medical Research Future Fund's emerging priorities and consumer driven research initiative.

The Government said the grants were open for "innovative high-quality research which [would] contribute to a greater understanding of the causes and underlying factors contributing to the development and progression of ovarian cancer".

"Early detection and finding a cure for ovarian cancer is a priority for this funding," Mr Hunt said.

For more information, go to: <https://bit.ly/37K777T>.

PRO MEDICUS

Pro Medicus says it will launch its Visage artificial intelligence accelerator at the Chicago Radiological Society of North America meeting from December 1 to 5, 2019.

Pro Medicus said its artificial intelligence (AI) accelerator included its Visage 7 AI research server and data curation and annotation tools, for a single platform that bridged research and diagnostic use.

The company said it used an open application programming interface to enable integration of third-party algorithms into its Visage 7 product.

Pro Medicus said it was working with the American College of Radiology (ACR) Data Science Institute to integrate its Visage 7 and semantic annotations into the ACR AI-Lab, which offered radiologists tools to learn AI basics and to participate directly in the creation, validation and use of health care AI.

The company said it would also demonstrate its Visage breast density classification algorithm at the conference, which was a work in progress in collaboration with the New Haven, Connecticut-based Yale New Haven Health.

Pro Medicus fell 62 cents or 2.4 percent to \$24.90 with 258,698 shares traded.

RESONANCE HEALTH

Resonance says it has a three-year agreement with Siemens Healthcare GmbH to distribute its Ferrismart artificial intelligence liver-iron quantifier.

Resonance said it would pay a commercially confidential commission to the Erlangen, Germany-based Siemens, who would offer Ferrismart to radiologists, radiographers and technicians through Siemens Healthineers digital marketplace.

The company said the marketplace provided healthcare professionals with direct open access to digital clinical products and remove the need for radiology to liaise with Resonance directly during the setup of magnetic resonance imaging machines.

Resonance said it would offer Ferrismart free of charge for 90 days to those who used Siemens' syngo.via imaging software with Ferrismart, after which consumers would need to enter into a services agreement with the company.

The company said it would retain the right to distribute and sell products outside the agreement and following an initial three-year period, the agreement would be automatically renewed for successive one-year periods.

Resonance was up 2.5 cents or 13.2 percent to 21.5 cents with 10.8 million shares traded.

CRESO PHARMA

Creso says it hopes to raise up to \$9,785,161 to repay the \$C3.9 million (\$A4.3 million) Pharmaciolo loan by November 30, 2019 and to fund its ongoing operations.

Creso said it hoped to raise up to \$5.5 million through the issue of up to 6,111,111 debt securities at a subscription price of 90 cents per share and a face value of \$1.00, up to 10,000 shares in a cleansing offer at an issue price of 20 cents per share to raise up to \$2,000, an additional convertible security facility to raise up to \$2.7 million, and up to \$1,585,161 through a placement of 8,299,271 shares at an issue price of 1.91 cents per share subject to shareholder approval.

The company said the offers would open on November 27, the debt note offer would close on November 28 and the cleansing offer would close on December 2, 2019.

Creso was in an extended suspension and last traded at 20 cents.

DORSAVI

Dorsavi says it has commitments for \$1.7 million in convertible notes and a placement at 2.7 cents a share and hopes to raise a further \$1.0 million in a share purchase plan.

Dorsavi said managing director Dr Andrew Ronchi, director Caroline Elliott and shareholders Starfish Technology Fund II Nominees A and Starfish Technology Fund II Nominees B raised \$360,000 of the \$560,000 placement, subject to shareholder approval.

The company said it had commitments to raise \$1,155,000 in convertible notes, maturing on December 6, 2022, with interest at 10 percent a year.

Dorsavi said the notes, subject to shareholder approval, would be convertible at 7.0 cents a note and would be at a 160 percent premium to the placement price.

The company said shareholders would be able to subscribe to up to \$29,960 in shares under the share plan at 2.8 cents a share, a 6.67 percent discount from the 30-day last and lowest traded market price.

Dorsavi said the record date for the share plan was November 27, it would open on December 3 and close on December 19, 2019 and the funds would be used for general working capital and to assist its push into the US market.

Dorsavi said Shaw and Partners was the lead manager to the placement.

Dorsavi was untraded at three cents.

IMPEDIMED

Impedimed says its Sozo bioimpedance spectroscopy device has US Food and Drug Administration 510(k) clearance for patients at-risk of “protein calorie malnutrition”. Impedimed said the clearance would allow it to use its Sozo device to track and report weight, muscle mass, fat mass and oedema over time in both healthy and unhealthy patient populations.

The company said the body composition parameters would be used by clinicians to support the assessment and diagnosis of at-risk protein calorie malnutrition patients. Impedimed said it would aid clinicians who used subjective global assessment tools, including the American Society for Parenteral and Enteral Nutrition guidelines, which defined changes in physical attributes as assessment criteria for protein calorie malnutrition patients.

Impedimed chief executive officer Richard Carreon said, “we are pleased that this submission to the FDA included real-world evidence”.

“This clearance will expand our clinical utility and footprint in the oncology space,” Mr Carreon said.

Impedimed fell half a cent or 2.8 percent to 17.5 cents with 3.4 million shares traded.

RESAPP HEALTH

Resapp says it will work with Sydney’s CoviU to combine its acute respiratory diagnostic test Resappdx-EU with CoviU’s browser-based telehealth software platform.

Resapp said it would access the more than 5,500 clinicians who used the CoviU platform, which allowed healthcare providers to offer services directly to patients through video consultation.

The company said it would negotiate with CoviU for a cost model of using the platform following completion of the four-month integration project.

Resapp was up half a cent or 1.85 percent to 27.5 cents with 5.3 million shares traded.

RESAPP HEALTH

Resapp says all resolutions at its annual general meeting passed, with up to 40 percent opposition to the issue of incentive options to directors.

Resapp said 100,265,582 votes (40.3%) were opposed to the options to Nathan Buzza, with 148,739,311 votes (59.7%) in favour.

The company said 84,429,624 votes (35.2%) were against the issue of incentive options to director Dr Tony Keating, with 155,175,269 votes (64.8%) in favor.

Resapp said 90,828,095 votes (37.9%) opposed to the issue to options to director Chris Ntoumenopoulos, with 148,776,798 votes (62.1%) in favor, and 89,847,420 votes (37.5%) were opposed to the issue of options to director Dr Roger Aston, with 149,757,473 votes (76.1%) in favor.

The company said 74,737,286 votes (29.3%) were opposed to managing director incentive options to Dr Keating, with 180,588,046 votes (70.7%) in favor.

Resapp said 62,817,606 votes (24.9%) were against re-approval of its employee incentive plan, with 189,701,439 votes (75.1%) in favor and 62,801,400 votes (23.9%) were against the 10 percent placement facility, with 199,908,449 votes (76.1%) in favour.

According to Resapp’s most recent Appendix 3B announcement, the company had 696,255,512 shares on issue, meaning that the 100,265,582 votes against the options to Mr Buzza amounted to 14.4 percent, sufficient to requisition extraordinary general meetings.

[OPTISCAN IMAGING](#)

Optiscan says all resolutions at its annual general meeting passed, with 19.0 percent opposed to the 10 percent placement facility.

Optiscan's meeting results notice said 46,546,184 votes (19.0%) were against the placement facility, with 197,967,114 votes (81.0%) in favor.

The notice said that the placement facility was a special resolution requiring a 75 percent majority to pass and all other resolutions faced 11.4 million to 14.3 million votes in opposition with more than 164 million and up to 234 million votes in favor.

According to Optiscan's most recent Appendix 3B announcement, the company had 470,178,800 shares on issue, meaning the 46,546,184 votes against the placement facility amounted to 9.9 percent, sufficient to requisition extraordinary general meetings.

Optiscan was up 0.4 cents or 10 percent to 4.4 cents.

[PAINCHEK](#)

Painchek says directors John Murray, Phillip Daffas, Adam Davey and Ross Harricks have sold 45,099,078 shares to fund a tax liability from the exercise of options.

Painchek said the shares were purchased by institutional investors at 20 cents a share.

The company said the new shares received from the exercise of options would be held in a 12-month voluntary escrow.

Painchek fell 4.5 cents or 17.0 percent to 22 cents with 21.95 million shares traded.

[IMUGENE](#)

Imugene has requested a trading halt "pending an announcement in relation to a proposed capital raising".

Trading will resume on December 2, 2019 or on an earlier announcement.

Imugene last traded at 4.4 cents.

[SIENNA CANCER DIAGNOSTICS](#)

Sienna has requested a voluntary suspension from trading pending the release of an announcement regarding a proposed capital raising (BD: Nov 26, 2019).

The company said it expected the suspension to last until November 29, 2019 or on the release of an earlier announcement.

Sienna last traded at 3.1 cents.

[NOXOPHARM](#)

Noxopharm has requested a trading halt "pending the release of an announcement relating to Darrt-1 results".

Last month, Noxopharm said Darrt-1 was a 22-patient, phase I, dose escalation study of direct and abscopal response to radiotherapy trial of Veyonda or NOX66 for end-stage prostate cancer (BD: Oct 21, 2019).

Trading will resume on December 2, 2019 or on an earlier announcement.

Noxopharm last traded at 32.5 cents.